Pulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 6,947 Shares

Pulmonx Co. (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 6,947 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $3.13, for a total value of $21,744.11. Following the transaction, the insider now owns 386,331 shares in the company, valued at $1,209,216.03. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Pulmonx Stock Up 6.7%

Shares of LUNG opened at $3.17 on Friday. The company has a market capitalization of $127.62 million, a price-to-earnings ratio of -2.20 and a beta of 0.52. Pulmonx Co. has a 52 week low of $2.83 and a 52 week high of $9.37. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The stock’s 50-day moving average price is $4.27 and its 200-day moving average price is $5.95.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. The business had revenue of $22.54 million during the quarter, compared to analysts’ expectations of $22.03 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, sell-side analysts predict that Pulmonx Co. will post -1.55 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in shares of Pulmonx in the fourth quarter valued at $43,000. ProShare Advisors LLC acquired a new stake in Pulmonx in the fourth quarter valued at $72,000. Stifel Financial Corp acquired a new stake in shares of Pulmonx during the fourth quarter worth about $81,000. Vontobel Holding Ltd. acquired a new stake in shares of Pulmonx during the first quarter worth about $82,000. Finally, SG Americas Securities LLC increased its position in shares of Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock worth $106,000 after purchasing an additional 3,310 shares in the last quarter. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on LUNG shares. D. Boral Capital reiterated a “buy” rating and set a $17.00 target price on shares of Pulmonx in a research note on Thursday, May 1st. Piper Sandler reissued an “overweight” rating and set a $9.00 price target (down previously from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Morgan Stanley initiated coverage on Pulmonx in a research note on Monday, March 10th. They issued an “equal weight” rating on the stock. Citigroup cut their target price on Pulmonx from $6.50 to $4.15 and set a “neutral” rating for the company in a research report on Thursday, May 22nd. Finally, Jefferies Financial Group initiated coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating for the company. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.53.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.